OC
APLS

Oppenheimer & Co’s Apellis Pharmaceuticals APLS Stock Holding History

Oppenheimer & Co’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,500
Closed -$206K – 1436
2024
Q1 		$206K Sell
3,500
-8,730
-71% -$556K ﹤0.01% 1334
2023
Q4 		$732K Buy
12,230
+391
+3% +$19.8K 0.01% 837
2023
Q3 		$450K Buy
11,839
+2,951
+33% +$130K 0.01% 986
2023
Q2 		$810K Buy
8,888
+1,548
+21% +$134K 0.02% 784
2023
Q1 		$484K Sell
7,340
-175
-2% -$10.1K 0.01% 955
2022
Q4 		$389K Buy
7,515
+132
+2% +$7K 0.01% 994
2022
Q3 		$504K Sell
7,383
-31
-0.4% -$1.83K 0.01% 897
2022
Q2 		$335K Buy
7,414
+55
+0.7% +$2.51K 0.01% 1065
2022
Q1 		$374K Buy
+7,359
New +$325K 0.01% 1106
2021
Q1 		– Sell
-4,267
Closed -$244K – 1434
2020
Q4 		$244K Sell
4,267
-3,182
-43% -$135K 0.01% 1166
2020
Q3 		$225K Buy
+7,449
New +$223K 0.01% 1109

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oppenheimer & Co's APLS Position: Q2 2024 in Review

Oppenheimer & Co sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 3,500 shares — an estimated $206K sold.

Oppenheimer & Co first reported a position in APLS in Q3 2020 and held it in 11 quarters. The position peaked at $810K in Q2 2023. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Oppenheimer & Co reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 3,500 Apellis Pharmaceuticals shares in Q2 2024, an estimated $206K.
  • Oppenheimer & Co first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 11 quarters.
  • Oppenheimer & Co's Apellis Pharmaceuticals position peaked at $810K in Q2 2023.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Oppenheimer & Co's 13F filing for Q2 2024, filed 8 Aug 2024.